INTRODUCTION
============

The p38 mitogen-activated protein kinase (MAPK) is a conserved gene \[[@b1-kjp-54-6-759]--[@b3-kjp-54-6-759]\] whose encoded protein transduces signals from the cell membrane to the nucleus in response to a wide variety of exogenous and endogenous stimuli \[[@b4-kjp-54-6-759]\]. Additionally, p38 regulates the expression of many cytokines, transcription factors, and cell surface receptors \[[@b5-kjp-54-6-759]\], leading to changes in cell differentiation and apoptotic processes.

As p38 proteins are widely involved in biological processes, their perturbation may lead to diseases. Many chemical compounds possessing p38 inhibitory properties have been identified. In particular, ML3404 and 2 other small molecule inhibitors, SB203580 and AZ10164773, dephosphorylate the active p38 molecule to produce its inactive form. Studies have assessed pharmaceutical drugs specifically targeting p38 to treat or cure certain human diseases, such as pulmonary artery remodeling \[[@b6-kjp-54-6-759]\], pancreatic cancer \[[@b7-kjp-54-6-759]\], and breast cancer \[[@b8-kjp-54-6-759]\]. Furthermore, p38 is not only an important signaling pathway member in the host, but also in invading pathogens.

Cystic echinococcosis (CE) is a cosmopolitan zoonosis caused by *E. granulosus*. It is most prevalent in countries where livestock (the intermediate host) are raised in association with dogs (the definitive host) \[[@b9-kjp-54-6-759]\]. The disease not only causes significant economic burdens \[[@b10-kjp-54-6-759]\], but also harms human health. At present, albendazole remains the first drug of choice for CE as recommended by WHO \[[@b11-kjp-54-6-759]--[@b13-kjp-54-6-759]\]; however, due to its heavy side effects and low absorption rate, albendazole is not recommended for a long-term hydatid therapy \[[@b14-kjp-54-6-759]--[@b16-kjp-54-6-759]\]. Therefore, identification of new drug targets is urgently required to develop improved therapies to cure CE.

Helminths rely on MAPK pathway signaling to mediate their biological processes, and signaling related molecules may be useful drug targets to combat parasitic infections and diseases. The p38 MAPK pathways play important roles in axon regeneration \[[@b17-kjp-54-6-759],[@b18-kjp-54-6-759]\], and p38 MAPK contributes to ciliary beating in the free-living miracidium stage of the platyhelminth parasite *Schistosoma mansoni* \[[@b19-kjp-54-6-759]\]. According to Patel et al. \[[@b20-kjp-54-6-759]\], p38 MAPK pathway activation within the filarial parasite *Brugia malayi* protects the parasite from destruction by host-produced reactive oxygen species (ROS). Thus, inhibition of this parasite protective pathway may result in therapeutic benefits for the treatment of filariasis by increasing the sensitivity of filarial parasites to ROS and other reactive intermediates. Indeed, Gelmedin et al. \[[@b21-kjp-54-6-759]\] identified a p38 homologue in *Echinococcus multilocularis* that was inhibited at lower doses of SB202190 and ML3403 than the human orthologue Hsp38α; furthermore, Lv et al. \[[@b22-kjp-54-6-759]\] confirmed the adequate in vitro scolicidal effects of a specific p38 MAPK inhibitor (SB202190) on *E. granulosus*. Thus, p38 MAPK may play an important role in *E. granulosus* and may represent a potential drug target for the treatment of CE. However, the function of the p38 MAPK in *E. granulosus*, remains uncharacterized, and it is unknown whether other p38 MAPK inhibitors exert on in vitro scolicidal effects on *E. granulosus*.

MATERIALS AND METHODS
=====================

Animals used in this study
--------------------------

*E. granulosus* vesicles and protoscolices were isolated from the livers of sheep naturally-infected with CE, which were obtained from a local commercial slaughterhouse. Two pathogen-free female New Zealand rabbits used for anti-Egp38 antibody preparation were purchased from the animal center of Xinjiang Medical University, housed in cages with a 12-hr light/dark cycle, and provided normal rabbit feed and water. All animals received humane care in compliance with the guidelines of the Medical Research Center, and animal procedures were approved by the Animal Care and User Committee and the Ethical Committee of the First Affiliated Hospital of Xinjiang Medical University, China (20081205-2).

Nucleic acid isolation, Egp38 cloning, and sequencing
-----------------------------------------------------

Total RNA was isolated from *E. granulosus* protoscolices using TRIzol reagent (Invitrogen Co., Beverly, Massachusetts, USA) according to the manufacturer's instructions. The cDNA was then synthesized from the purified RNA according to the instructions included with the reverse transcription kit (Invitrogen) and used as a template to amplify the Egp38 cDNA with the primers p38-5EC (5′-GTGCCCGATGTAAATGAGCG-3′) and p38-3EC (5′-CGCGTTGATTGGCGAGTAC-3′) \[[@b21-kjp-54-6-759]\]. The following thermal cycling conditions were used: 35 cycles of 30 sec at 94°C, 1 min at 53°C, and 1 min at 72°C. The amplified fragment was cloned into the pMD18-T vector with a TA cloning kit (Takara Co., Dalian, China) and verified by sequencing (Shanghai Sangon Co., Shanghai, China).

Bioinformatics software analysis
--------------------------------

Amino acid sequences of the p38 MAPK homologous genes in *E. multilocularis, Homo sapiens, Drosophila melanogaster, Caenorhabditis elegans*, and *Saccharomyces cerevisiae* were downloaded from GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>) and compared using DNAMAN 5.0. Phylogenetic trees were constructed with the software tool MegAlign for multiple sequence alignment. Catalytic domains were predicted with a simple modular architecture research tool (SMART; <http://smart.embl-heidel-berg.de>) \[[@b23-kjp-54-6-759]\]. GraphPad Prism software (GraphPad Software) version 5 was used for statistical analyses.

Structure prediction using homology modeling
--------------------------------------------

The 3 dimensional-structures of the Egp38 proteins were predicted by submitting the amino acid sequences to the SwissModel Automatic Modeling server (<http://Swissmodel.expasy.org>) \[[@b24-kjp-54-6-759]\]. The Egp38 homology model was calculated based on the crystal structure of the *Cryptosporidium* Ser/Thr protein kinase template (3eb0A). The EmMPK2 homology model was calculated based on the crystal structure of the human tau Ser/Thr protein kinase template (1j1bB). Structural comparisons and figure generation were carried out using DeepView/Swiss-Pdbviewer 4.01 \[[@b25-kjp-54-6-759]\].

Quantitative real-time PCR (qRT-PCR) analysis
---------------------------------------------

Equal amounts of *E. granulosus* vesicles and protoscolices cDNA were employed for qRT-PCR to determine the expression of Egp38 using the primers p38-5q (5′-ACTCAACTACACCAGCAAGAAG-3′) and p38-3q (5′-TCCTACAGGCTCATCACTCTC-3′) or elp using the primers elp-5q (5′-CGGGAGGGTAATGACAAG-3′) and elp-3q (5′-GGAAGTAACCGTAGTGATGGAG-3′). The following thermal cycling conditions were employed: initiation with a 10 min denaturation at 95°C, followed by 40 cycles of 30 sec at 94°C and 60 sec at 60°C. The relative gene expression of Egp38 was calculated via the 2^−ΔΔCT^ method \[[@b26-kjp-54-6-759]\]; elp was used as a housekeeping gene \[[@b27-kjp-54-6-759]\]. In all cases, each PCR trial was performed in triplicate and repeated at least 3 times.

Heterologous expression in *Escherichia coli* and purification of recombinant proteins
--------------------------------------------------------------------------------------

Egp38 was expressed in *E. coli* using the pET-28a system. Briefly, the entire Egp38 open reading frame (ORF) was PCR-amplified from the plasmid pMD18-T-Egp38 using the primers p38-F-28a (5′-GGAATTCATGCCCGATGTAAATGA-3′) and p38-R-28a (5′-GTCGACCGTTGATTGGCGAGTA-3′), employing the conditions described above, and cloned into the pET-28a vector with EcoR I and Sal I, resulting in an N-terminal in-frame fusion with a hex-histidine tag. The production of recombinant proteins after induction with 0.1 mM IPTG was carried out according to the pET user manual. The recombinant Egp38 proteins were purified from *E. coli* lysates under native conditions via affinity chromatography against the hex-histidine tag. After collecting recombinant *E. coli* by centrifugation (6,000 g, 20 min, 4°C) from 2 L of culture, the pellet was resuspended in 20 ml of lysis buffer (300 mM NaCl, 50 mM sodium-phosphate buffer at pH 8.0, 10 mM imidazole). Cell debris was removed by centrifugation, and the supernatant was transferred to 4 ml of a nickel bead slurry and equilibrated with lysis buffer. After overnight rotation at 4°C, beads were washed 3 times with 300 ml of washing buffer (300 mM NaCl, 50 mM sodium-phosphate buffer at pH 8.0, 20 mM imidazole). Recombinant protein was then extracted with 6 ml elution buffer I (300 mM NaCl, 50 mM sodium-phosphate buffer at pH 8.0, 250 mM imidazole) and 6 ml elution buffer II (300 mM NaCl, 50 mM sodium-phosphate buffer at pH 8.0, 500 mM imidazole). Protein-containing fractions were pooled and dialyzed overnight against PBS at 4°C.

Antibodies, western blotting analysis, and immunohistochemistry
---------------------------------------------------------------

To detect Egp38 in *Echinococcus* larval stages, we generated an anti-Egp38 antibody in rabbits by carrying out 4 rounds of immunization with recombinant Egp38. As the pTGpY phosphorylation motif is highly conserved in Egp38, a commercially available antibody for the phosphorylated (pTGpY) form of p38 MAPK (Promega, Mannheim, Germany) was used to detect phosphorylated Egp38. Rabbit anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, California, USA) was used to detect β-actin of *E. granulosus*. For western blotting, vesicles and protoscolices lysates from CE sheep were produced, separated on 12% acrylamide gels, and electro-transferred to nitrocellulose membranes. Detection was performed with the above-mentioned antibodies according to the manufacturer's instructions, using an anti-rabbit (whole molecule) IgG-peroxidase antibody as the secondary antibody (Sigma-Aldrich, Taufkirchen, Germany). For immunohistochemistry, vesicles and protoscolices from infected CE sheep were isolated and embedded in paraffin for sectioning and antibody staining. Immunohistochemistry was then performed with the phospho-specific Egp38 antibody (see above) according to a previously established protocol \[[@b28-kjp-54-6-759]\].

Drug treatment of protoscolices
-------------------------------

Freshly isolated *E. granulosus* protoscolices were washed in sterile PBS (Gibco-BRL, Eggenstein, Germany) and incubated in 96-well plates (approximately 400 protoscolices per well) in the presence of culture medium (89% Dulbecco's minimal essential medium, 10% fetal calf serum, 1% penicillin-streptomycin solution). ML3403 was dissolved in dimethylsulphoxide (DMSO). Negative control groups did not contain DMSO or ML3403 (Calbiochem, Gibbstown, New Jersey, USA). The DMSO group which had 2 μl of DMSO per well is solvent control. The 7.5 μM, 15 μM, 30 μM, and 60 μM ML3403 groups contained 2 μl of the appropriate concentration of ML3403 per well to achieve the desired final concentrations. At each time point (0, 1, 2, 3, 4, and 5 days), 3 wells for each group were stained with eosin, and the viability was immediately assessed by counting under a microscope. Red stained protoscolices were dead, and protoscolies lacking color staining were alive. The survival percentage was calculated as the number of live protoscolices divided by the total number of live and dead protoscolices. All experiments were performed independently in quadruplicate.

In addition, freshly prepared protoscolices were treated with 60 μM ML3403 for 4 hr in vitro, to detect native or phosphorylated Egp38 by western blotting.

TGF-β1 treatment of protoscolices
---------------------------------

Freshly prepared protoscolices were acclimated via cultivation in culture medium (99% Dulbecco's minimal essential medium, 1% penicillin-streptomycin solution) for 7 days, then treated with 1 nM TGF-β1 (R&D Systems, Minneapolis, Minneapolis, USA) \[[@b29-kjp-54-6-759]\] for 24 hr. At each time point (0 hr, 4 hr, 8 hr, and 24 hr), protoscolices were removed to detect native or phosphorylated Egp38 by western blotting.

RESULTS
=======

Characteristics of Egp38
------------------------

The entire Egp38 ORF sequence comprised 1,107 bp and 368 codons (excluding the TGA stop codon). As shown in [Fig. 1](#f1-kjp-54-6-759){ref-type="fig"}, the encoded protein (368 amino acids, 42 kDa) exhibited significant homology with p38 proteins in mammals, insects, nematodes, yeasts, and plants. The p38 homologue EmMPK2 from *E. multilocularis* demonstrated the highest level of homology (98.6% identity). Lower levels (43.0--61.9% identity) of homology were shared with p38 homologues from a wide variety of phylogenetically distinct animals, including mammals, insects, and nematodes. Thus, we designated the corresponding *E. granulosus* cDNA and the encoded 42 kDa protein as Egp38.

Based on EmMPK2 sequence analysis \[[@b21-kjp-54-6-759]\], the amino acid sequence of Egp38 exhibits many characteristics of p38 homologues. A Ser/Thr protein kinase catalytic domain between residues Tyr^25^ and Phe^309^ of Egp38 was identified with the SMART software package \[[@b23-kjp-54-6-759]\]. Many conserved amino acid residues in eukaryotic protein kinases were also observed in EgP38 and at corresponding positions ([Fig. 1](#f1-kjp-54-6-759){ref-type="fig"}). Furthermore, Egp38 contains a T-G-Y dual phosphorylation site in the activation loop of the kinase domain.

We investigated the phylogenetic relatedness of p38 homologue sequences. The constructed evolutionary tree revealed the close identity of p38 in *E. granulosus* and *E. multilocularis* to orthologs in *Schistosoma japonicum* and yeast, but divergence from p38 in nematodes, filarial parasites, amphibians, and mammals ([Fig. 2](#f2-kjp-54-6-759){ref-type="fig"}).

Homology model of Egp38
-----------------------

The models for Egp38, EmMPK2, and p38α were very similar ([Fig. 3A--C](#f3-kjp-54-6-759){ref-type="fig"}), particularly in terms of the catalytic domain, as illustrated by color-coding. Only minimal differences were observed between the N-terminal regions of Egp38 (Pro^22^-Met^110^) and EmMPK2 (Asp^23^-Met^110^). In contrast, the N- and C-terminal regions of p38α ([Fig. 3C](#f3-kjp-54-6-759){ref-type="fig"}) were very different compared to Egp38 and EmMPK2; in particular, p38α included 2 longer helices (colored sky blue and red).

Egp38 expression during the larval stages of *E. granulosus*
------------------------------------------------------------

As shown in [Fig. 4](#f4-kjp-54-6-759){ref-type="fig"}, there were no significant differences between the vesicles and protoscolices of *E. granulosus*, indicating the constitutive expression of Egp38 cDNA, during the larval stages. An anti-Egp38 antibody and an antibody for the phosphorylated (pTGpY) form of p38 MAPK were employed to detect Egp38 and its active form, respectively. Egp38 and its active form were both identified in *Echinococcus* vesicles and protoscolices lysates, and the proteins migrated at approximately 45 kDa.

Localization of Egp38
---------------------

As shown in [Fig. 6A and D](#f6-kjp-54-6-759){ref-type="fig"}, both the germinal layer of the vesicle and the defined structures of the protoscolex reacted with rabbit-anti Egp38 immune sera, which detected total Egp38. In the vesicles, strong staining was observed in the cytoplasm and nuclei of the germinal layer cells. In the protoscolices, staining was present in the tissue surrounding the rostellum and in the suckers. As shown in [Fig. 6B and E](#f6-kjp-54-6-759){ref-type="fig"}, localization of phosphorylated Egp38 was similar to that of the total Egp38 in the germinal layer of the vesicle and protoscolex. However, phosphorylated Egp38 was localized in the cytoplasm and nuclei of certain germinal layer cells in the vesicles.

Taken together, the western blotting and immunohistochemistry findings from parasite lysates indicated that Egp38 was constitutively present throughout the *Echinococcus* larval development stages.

Effects of p38 MAPK inhibitors on cultivated protoscolices in vitro
-------------------------------------------------------------------

To test the effects of p38 MAPK inhibitors on *E. granulosus* larvae, we employed ML3403 and examined the phosphorylation status of Egp38. After treatment with 60 μM ML3403 for 4 hr, the phospho-Egp38 band nearly disappeared, while the phospho-Egp38 band in the control group, with or without DMSO, was clearly present ([Fig. 7B](#f7-kjp-54-6-759){ref-type="fig"}); thus, the p38 MAPK inhibitor effectively blocked Egp38 phosphorylation activity in the parasite.

On the 3rd day, the viability of the protoscolices treated with 30 and 60 μM ML3404 ([Fig. 7A](#f7-kjp-54-6-759){ref-type="fig"}) began to decline. On the 5th day, the protoscolices viability of the 60 μM ML3404 treatment group declined to only 7.3% of the total ([Fig. 7A](#f7-kjp-54-6-759){ref-type="fig"}). However, protoscolices survival in the normal group, the DMSO group, the 7.5 μM ML3404 group and the 15 μM ML3404 group remained unaffected ([Fig. 7A](#f7-kjp-54-6-759){ref-type="fig"}, [Supplementary Fig. S1](#s1-kjp-54-6-759){ref-type="supplementary-material"}).

Effects of human TGF-β1 on cultivated protoscolices in vitro
------------------------------------------------------------

To investigate whether human TGF-β1 exerts effects via Egp38, we treated *E. granulosus* protoscolices with human TGF- β1 for 24 hr in vitro. Human TGF-β1 activated the phosphorylation of Egp38 over time. At 24 hr, the phosphorylation levels of Egp38 were increased by approximately 4-folds ([Fig. 8](#f8-kjp-54-6-759){ref-type="fig"}).

DISCUSSION
==========

The p38 kinase homologues have been identified in many helminths, such as *E. multilocularis, S. japonicum, S. mansoni,* and *B. malayi*, and play crucial roles in supporting parasite survival. Our study yielded evidence supporting the existence of a p38 homologue in *E. granulosus*. The mRNA and the active protein form of Egp38 were expressed in the germinal layers of vesicles and protoscolices. The active form of Egp38 was expressed in both the vesicles and protoscolices, but not in the accompanying cystic fluid (data not shown). This intracellular-restricted expression pattern indicates that Egp38 is a bioactive molecule during the larval stages of *E. granulosus* but does not interact with the host directly because it is not secreted by *E. granulosus* cells. Furthermore, the active form of Egp38 was observed in the cytoplasm and nuclei of the vesicle germinal layer and protoscolices, which agrees with the predominant localization of phosphorylated forms of p38-like kinases in animal cells \[[@b31-kjp-54-6-759]\]. Thus, the function of Egp38 is likely similar to that of other p38 homologous genes and transduces extracellular signaling to the nucleus.

In many parasites, the p38 MAP homologue has been identified as a good candidate for the development of drugs to combat parasitic diseases \[[@b20-kjp-54-6-759],[@b21-kjp-54-6-759]\]. According to Lv H et al. \[[@b22-kjp-54-6-759]\], an inhibitor of Egp38, SB202190, exhibits parasiticidal activity in vitro; however, it is unclear whether SB202190 kills the larvae by inhibiting the activity of Egp38 or if Egp38 is an anti-CE drug target. In this work, Egp38 influenced the survival of *E. granulosus* larval stages. Inhibition of the active form of Egp38 in protoscolices, via treatment with the p38-specific inhibitor ML3403 resulted in cell death; thus, Egp38 is important for protoscolex survival. Egp38 may be a viable drug target to cure CE.

The p38 MAPKs are a class of mitogen-activated protein kinases that respond to stress stimuli, such as cytokines (TGF-β1) \[[@b32-kjp-54-6-759]\], and Egp38 contains typically characteristic domains of p38 homologues. TGF-β1, an important cytokine that regulates Smad and p38 signaling pathways in mammals, is highly expressed in the pericystic layer of the *echinococcus* vesicle cyst \[[@b33-kjp-54-6-759]\], and in sera of CE patients \[[@b34-kjp-54-6-759]\] and mice infected with *E. granulosus* \[[@b35-kjp-54-6-759]\]. Human TGF-β1 activated Egp38, indicating the ability of the parasite to respond to host TGF-β1 and control its parasitism by activating the Egp38 signaling pathway. According to Zhang et al. \[[@b27-kjp-54-6-759]\], human TGF-β1 activates Smad signaling pathways in *E. granulosus*. Therefore, human TGF-β1 appears to exert multiple functions on *E. granulosus* by regulating the Smad and Egp38 signaling pathways.

EgMKK1 in *E. granulosus*, whose sequence shares high identity with EmMKK1 in *E. multilocularis* \[[@b36-kjp-54-6-759]\], closely resembles members of the MKK3/6-MAPKK family (data not shown). MKK3/6-MAPKK proteins are upstream signaling molecules of p38 MAPK. Thus far, Egp38 and EgMKK1 are the only 2 members of the p38 MAPK pathway identified in *E. granulosus*, but there are certainly many other related signaling molecules belonging to this pathway that, when identified, will provide significant insights into the precise mechanisms employed by Egp38.

Collectively, the newly discovered Egp38 MAP kinase will be useful for exploring the molecular mechanisms underlying the interplay between host TGF-β1 and *E. granulosus* and in the development of new anti-parasite drugs to cure CE.

Supplementary materials
=======================

###### 

Protoscolices of *E. granulosus* treated with drugs in vitro. (A) Protoscolices after 5 days of cultivation under normal (untreated) conditions, or with (B) DMSO, (C) 7.5 μM ML3403, (D) 15 μM ML3403, (E) 30 μM ML3403, and (F) 60 μM ML3403.
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![Alignment of the deduced Egp38 amino acid sequence with other relevant sequences. Amino acid residues that are conserved in at least 2 proteins are indicated in white on a black background. Homologies of the aligned proteins to Egp38 are indicated at the end of the alignment (% identity). Asterisks denote residues that are highly conserved in eukaryotic protein kinases \[[@b37-kjp-54-6-759]\]. Black triangles indicate conserved Asp residues within the docking domain \[[@b38-kjp-54-6-759]\]. Thr and Tyr residues of the conserved T-G-Y motif are denoted by 'P'. Black rectangles indicate residues in the yeast HOG1 that, when mutated, lead to constitutive activation \[[@b39-kjp-54-6-759]\]. Circles above the alignment indicate residues in the human p38 MAPK-α that are involved in the binding of pyridinyl imidazole inhibitors \[[@b39-kjp-54-6-759]\]. The activation loop is marked by a dotted line below the aligned sequence. Egp38 (ACT21201.1), *E. multilocularis* p38 MAPK (EmMPK2; CAQ34816.1), *H. sapiens* p38 MAPK-α (Hsp38α; Q16539), *D. melanogaster* p38 MAPK (DmMK14A; O62618), *C. elegans* stress-activated protein kinase PMK-1 (CePMK1; Q17446), and *S. cerevisiae* HOG-1 (ScHOG1; P32485).](kjp-54-6-759f1){#f1-kjp-54-6-759}

![Phylogenetic tree of p38 in *E. granulosus* and other relevant species. *E. granulosus* p38 MAPK (egp38.pro; ACT21201.1), *E. multilocularis* p38 MAPK (emmpk2.pro; CAQ34816.1), *H. sapiens* p38 MAPK-α (hsp38-alpha.pro; Q16539), *H. sapiens* p38 MAPK-β (hsp38-beta.pro; Q15759), *H. sapiens* p38 MAPK-γ (hsp38-gama.pro; P53778), *H. sapiens* p38 MAPK-δ (hsp38-delta.pro; O15264), *C. elegans* stress-activated protein kinase PMK-1 (cepmk1.pro; Q17446), *Danio rerio* Mapk14b protein (drmapk14.pro; AAH63937.1), *Xenopus tropicalis* MAPK 11 (xtmpk11.pro; NP_001098754.1), *S. japonicum* MAPK14a (sjmpk14; CAX72870), *Brugia malayi* p38 map kinase family protein 2 isoform b (bmp38.pro; A8PQS0), *Loa loa* CMGC/MAPK/p38 protein kinase (llp38.pro; XP_003141640), *Wuchereria bancrofti* CMGC/MAPK/P38 protein kinase (wbp38.pro; WUBG14523.1 of Broad Institute Filarial Database), *D. melanogaster* p38 MAPK (dmmk14.pro; O62618), and yeast HOG-1 (schog1.pro; P32485).](kjp-54-6-759f2){#f2-kjp-54-6-759}

![Molecular models of the tertiary structure. (A) Surface rendering of Egp38. (B) Surface rendering of EmMPK2. (C) Surface rendering of Hsp38α. Individual sub-domains (helix and strand) are colored in the following order: gray, deep blue, sky blue, green, kelly green, yellow, khaki, orange, and red.](kjp-54-6-759f3){#f3-kjp-54-6-759}

![Egp38 mRNA levels in larval stages.](kjp-54-6-759f4){#f4-kjp-54-6-759}

![Egp38 antibody reactivities. (A) Total proteins were separated by SDS-PAGE. (B) The Egp38 protein was identified with an anti-p38 antibody. (C) The Egp38 protein was identified with an anti-phospho-p38 (pTGpY) antibody. (D) β-actin protein of *E. granulosus* was identified with an anti-β-actin antibody. Lane 1, *E. granulosus* protoscolices lysates; lane 2, *E. granulosus* vesicle lysates. Arrows indicate the interest proteins.](kjp-54-6-759f5){#f5-kjp-54-6-759}

![Immunohistochemical detection of Egp38 in *E. granulosus* larval stages. Paraffin sections of protoscolices and vesicles isolated from CE sheep were probed with rabbit anti-Egp38 (A, D) and anti-phospho-p38 primary antibodies (B, E) and developed with a peroxidase-coupled goat anti-rabbit IgG secondary antibody or with secondary antibody alone (C, F). The following structures are indicated: GL, germinal layer; LL, laminated layer; P, protoscolex; R, rostellum; S, sucker. Arrows indicate the locations of Egp38 or the active form of Egp38. Scale bar=50 μm.](kjp-54-6-759f6){#f6-kjp-54-6-759}

![Effects of the p38 MAPK inhibitor ML3403 on the viability of cultivated protoscolices in vitro. (A) Survival rates of protoscolices after 5 days of treatment with different concentrations of ML3403. (B) Egp38 activity in inhibitor-treated protoscolices. Protoscolices were incubated with the inhibitor ML3403 (60 μM) for 4 hr (lane 4). Lysates were examined by western blotting using antibodies against phosphorylated p38 MAPK (P-Egp38) as well as non-phosphorylated (Egp38). Lane 1, protoscolices prior to treatment. Lane 2, untreated protoscolices grown for 4 hr. Lane 3, DMSO treatment for 4 hr. Lane 4, ML3403 treatment for 4 hr.](kjp-54-6-759f7){#f7-kjp-54-6-759}

![EgP38 phosphorylation in protoscolices cultivated with TGF-β1 in vitro. (A) Time-dependent phosphorylation of EgP38 following TGF-β1 treatment of protoscolices; immunoblotting was performed with either antibody as shown in [Fig. 7](#f7-kjp-54-6-759){ref-type="fig"}. (B) Quantification by densitometry (n=4±SD; \**P*\<0.01 compared the with 0 hr group).](kjp-54-6-759f8){#f8-kjp-54-6-759}
